TrialFuture oncology (London, England)2025

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line

Scott Kopetz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.